SEC Form 4 · accession 0001179110-17-006946
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Connie Matsui
Director
Period of report
May 8, 2017
Accepted (ET)
May 9, 2017 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 8, 2017 | M | 10,000 | $10.37 | A | 247,388 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $10.37 | May 8, 2017 | M | 10,000 | D | — | May 15, 2017 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1These options became fully vested and exercisable on the date immediately preceding the date of the annual stockholders' meeting following the date of grant.